EZH2 and breast cancer: Our previous study has demonstrated that ANCR interacts with EZH2 and promotes the CDK1-EZH2 binding to increase its phosphorylation at Thr-345 and Thr-487 residues, resulting in EZH2 ubiquitination and degradation in breast cancer cells [24].